As of 2026-09-13, the EV/EBITDA ratio of CytomX Therapeutics Inc (CTMX) is -8.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTMX's latest enterprise value is 699.01 mil USD. CTMX's TTM EBITDA according to its financial statements is -86.15 mil USD. Dividing these 2 quantities gives us the above CTMX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.0x - 15.9x | 13.0x |
| Forward P/E multiples | 12.2x - 17.5x | 16.6x |
| Fair Price | (4.76) - (6.22) | (5.78) |
| Upside | -244.8% - -289.1% | -275.6% |
| Date | EV/EBITDA |
| 2026-09-04 | -9.17 |
| 2026-09-03 | -9.10 |
| 2026-09-02 | -9.20 |
| 2026-09-01 | -9.07 |
| 2026-08-31 | -8.29 |
| 2026-08-28 | -7.91 |
| 2026-08-27 | -8.44 |
| 2026-08-26 | -8.19 |
| 2026-08-25 | -8.32 |
| 2026-08-24 | -8.11 |
| 2026-08-21 | -8.09 |
| 2026-08-20 | -8.11 |
| 2026-08-19 | -8.82 |
| 2026-08-18 | -8.37 |
| 2026-08-17 | -8.52 |
| 2026-08-14 | -8.29 |
| 2026-08-13 | -8.27 |
| 2026-08-12 | -8.62 |
| 2026-08-11 | -8.52 |
| 2026-08-10 | -8.49 |
| 2026-08-07 | -8.54 |
| 2026-08-06 | -8.32 |
| 2026-08-05 | -8.27 |
| 2026-08-04 | -8.19 |
| 2026-08-03 | -7.81 |
| 2026-07-31 | -7.63 |
| 2026-07-30 | -8.09 |
| 2026-07-29 | -7.81 |
| 2026-07-28 | -7.94 |
| 2026-07-27 | -8.01 |
| 2026-07-24 | -7.99 |
| 2026-07-23 | -8.21 |
| 2026-07-22 | -8.21 |
| 2026-07-21 | -8.44 |
| 2026-07-20 | -8.69 |
| 2026-07-17 | -8.95 |
| 2026-07-16 | -9.06 |
| 2026-07-15 | -9.10 |
| 2026-07-14 | -9.05 |
| 2026-07-13 | -9.15 |
| 2026-07-10 | -9.30 |
| 2026-07-09 | -9.79 |
| 2026-07-08 | -9.48 |
| 2026-07-07 | -9.50 |
| 2026-07-06 | -9.43 |
| 2026-07-02 | -9.45 |
| 2026-07-01 | -8.90 |
| 2026-06-30 | -9.28 |
| 2026-06-29 | -9.25 |
| 2026-06-26 | -8.39 |